Expanded access to ziftomenib for leukemia patients
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial offers expanded access to the experimental drug ziftomenib for adults with acute leukemias who have no other treatment options. It may be especially relevant if you have AML with NPM1 mutation or KMT2A rearrangement.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL).
- You are 18 years or older.
- You have already tried standard treatments that did not work, and there is no other good treatment option available.
- You are not able to join any ongoing clinical trial for this drug, for example because of where you live.
- If you have AML with a KMT2A rearrangement, the drug will be given together with other FDA-approved therapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral drug called ziftomenib for people with a type of acute myeloid leukemia (AML) that has certain genetic changes (NPM1 mutation or KMT2A rearrangement) and who are not able to receive standard chemotherapy. The goal is to see if ziftomenib can help control the leukemia.
This Phase 1 trial tests how safe and tolerable ziftomenib is when combined with standard AML medicines (like venetoclax and azacitidine, and other chemo options) in people with AML. It’s for AML patients who have specific genetic changes (NPM1 mutation or KMT2A rearrangement) and helps doctors find the best, safest dose plan.
This trial tests a new drug combination called ziftomenib for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. Researchers will check how safe it is and what side effects happen.
This trial tests a new drug, ziftomenib, added to standard chemotherapy for adults with untreated acute myeloid leukemia (AML) who have specific gene changes (NPM1 mutation or KMT2A rearrangement). It aims to see if the combination works better than standard treatment alone.
This trial tests a new drug called ziftomenib in patients whose acute myeloid leukemia (AML) has come back or stopped responding to treatment and has a specific genetic change called an NPM1 mutation. The drug targets a protein called menin that may help cancer cells grow, and researchers hope it could help patients who have run out of standard treatment options.
This trial tests a combination of two experimental drugs, ziftomenib and mezigdomide, for people whose acute myeloid leukemia (AML) has come back or not responded to prior treatment. It's designed for those whose leukemia cells have a specific genetic change (KMT2A rearrangement or NPM1 mutation).
Hear when a new Acute Lymphoblastic Leukemia, With KMT2A Rearrangements trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.